Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...
Tectonic Therapeutic reports ‘positive’ data from Phase 1b trial for TX45
Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...
Tectonic Therapeutic stock soars on positive trial data
Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) surged 40% following the announcement of encouraging interim data from a Phase 1b trial for its TX45 treatment in patients with Group 2 Pulmonary ...
Nature7d
Alveolar Capillary Dysplasia and Associated Pulmonary Conditions
This condition is characterized by abnormal development of the lung's capillary network, which can lead to persistent pulmonary arterial hypertension (PAH). Recent research has focused on ...
Hosted on MSN1mon
Have the New Pulmonary Hypertension Drugs Changed the Game?
"We also await data of the use of sotatercept in post-capillary pulmonary hypertension ([WHO] group 2). If the CADENCE study is positive, this would be a game changer," according to Highland.
University of Sheffield4y
Our research
This resource now underpins a major proportion of our current research studies as we try to better understand the molecular pathogenesis of pulmonary hypertension. Project Title: Elucidating the role ...